|
1
|
Pohar SL and Allyson Jones C: The burden
of Parkinson disease (PD) and concomitant comorbidities. Arch
Gerontol Geriatr. 49:317–321. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H
and Wang Z: Global trends in the incidence, prevalence, and years
lived with disability of Parkinson's disease in 204
countries/territories from 1990 to 2019. Front Public Health.
9(776847)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
James SL, Abate D, Abate KH, Abay SM,
Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J,
Abdelalim A, et al: Global, regional, and national incidence,
prevalence, and years lived with disability for 354 diseases and
injuries for 195 countries and territories, 1990-2017: A systematic
analysis for the global burden of disease study 2017. Lancet.
392:1789–1858. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Feigin VL, Nichols E, Alam T, Bannick MS,
Beghi E, Blake N, Culpepper WJ, Dorsey ER, Elbaz A, Ellenbogen RG,
et al: Global, regional, and national burden of neurological
disorders, 1990-2016: A systematic analysis for the global burden
of disease study 2016. Lancet Neurol. 18:459–480. 2019.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wanneveich M, Moisan F, Jacqmin-Gadda H,
Elbaz A and Joly P: Projections of prevalence, lifetime risk, and
life expectancy of Parkinson's disease (2010-2030) in France. Mov
Disord. 33:1449–1455. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Scorza FA, Fiorini AC, Scorza CA and
Finsterer J: Cardiac abnormalities in Parkinson's disease and
Parkinsonism. J Clin Neurosci. 53:1–5. 2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Noack C, Schroeder C, Heusser K and Lipp
A: Cardiovascular effects of levodopa in Parkinson's disease.
Parkinsonism Relat Disord. 20:815–818. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
van Camp G, Flamez A, Cosyns B, Weytjens
C, Muyldermans L, Van Zandijcke M, De Sutter J, Santens P, Decoodt
P, Moerman C and Schoors D: Treatment of Parkinson's disease with
pergolide and relation to restrictive valvular heart disease.
Lancet. 363:1179–1183. 2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kho J, Ioannou A, Mandal AKJ and Missouris
CG: Donepezil induces ventricular arrhythmias by delayed
repolarisation. Naunyn Schmiedebergs Arch Pharmacol. 394:559–560.
2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Palma JA and Kaufmann H: Treatment of
autonomic dysfunction in Parkinson disease and other
synucleinopathies. Mov Disord. 33:372–390. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Coon EA, Cutsforth-Gregory JK and
Benarroch EE: Neuropathology of autonomic dysfunction in
synucleinopathies. Mov Disord. 33:349–358. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Chen Z, Li G and Liu J: Autonomic
dysfunction in Parkinson's disease: Implications for
pathophysiology, diagnosis, and treatment. Neurobiol Dis.
134(104700)2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Arici Duz O and Helvaci Yilmaz N:
Nocturnal blood pressure changes in Parkinson's disease:
Correlation with autonomic dysfunction and vitamin D levels. Acta
Neurol Belg. 120:915–920. 2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sommer S, Aral-Becher B and Jost W:
Nondipping in Parkinson's disease. Parkinsons Dis.
2011(897586)2011.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Velseboer DC, de Haan RJ, Wieling W,
Goldstein DS and de Bie RMA: Prevalence of orthostatic hypotension
in Parkinson's disease: A systematic review and meta-analysis.
Parkinsonism Relat Disord. 17:724–729. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yalcin A, Atmis V, Cengiz OK, Cinar E,
Aras S, Varli M and Atli T: Evaluation of cardiac autonomic
functions in older Parkinson's disease patients: A cross-sectional
study. Aging Dis. 7:28–35. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Palma JA and Kaufmann H: Epidemiology,
diagnosis, and management of neurogenic orthostatic hypotension.
Mov Disord Clin Pract. 4:298–308. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jain S and Goldstein DS: Cardiovascular
dysautonomia in Parkinson disease: From pathophysiology to
pathogenesis. Neurobiol Dis. 46:572–580. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Senard JM, Raï S, Lapeyre-Mestre M, Brefel
C, Rascol O, Rascol A and Montastruc JL: Prevalence of orthostatic
hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry.
63:584–589. 1997.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Blaho A, Šutovský S, Valkovič P, Šiarnik
P, Sýkora M and Turčáni P: Decreased baroreflex sensitivity in
Parkinson's disease is associated with orthostatic hypotension. J
Neurol Sci. 377:207–211. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Nakamura T, Hirayama M, Hara T, Mizutani
Y, Suzuki J, Watanabe H and Sobue G: Role of cardiac sympathetic
nerves in preventing orthostatic hypotension in Parkinson's
disease. Parkinsonism Relat Disord. 20:409–414. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Shibata M, Morita Y, Shimizu T, Takahashi
K and Suzuki N: Cardiac parasympathetic dysfunction concurrent with
cardiac sympathetic denervation in Parkinson's disease. J Neurol
Sci. 276:79–83. 2009.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Goldstein DS: Dysautonomia in Parkinson's
disease: Neurocardiological abnormalities. Lancet Neurol.
2:669–676. 2003.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Goldstein DS, Pechnik S, Holmes C, Eldadah
B and Sharabi Y: Association between supine hypertension and
orthostatic hypotension in autonomic failure. Hypertension.
42:136–142. 2003.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Galvin JE, Lee VMY and Trojanowski JQ:
Synucleinopathies: Clinical and pathological implications. Arch
Neurol. 58:186–190. 2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Iodice V, Low DA, Vichayanrat E and
Mathias CJ: Cardiovascular autonomic dysfunction in MSA and
Parkinson's disease: Similarities and differences. J Neurol Sci.
310:133–138. 2011.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cuoco S, Carotenuto I, Cappiello A,
Scannapieco S, Russillo MC, Andreozzi V, Forino L, Amboni M,
Picillo M, Erro R, et al: Relationship between orthostatic
hypotension and cognitive functions in multiple system atrophy: A
longitudinal study. Front Neurol. 12(711358)2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
de la Sierra A, Gorostidi M, Banegas JR,
Segura J, de la Cruz JJ and Ruilope LM: Nocturnal hypertension or
nondipping: Which is better associated with the cardiovascular risk
profile? Am J Hypertens. 27:680–687. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Espay AJ, LeWitt PA, Hauser RA, Merola A,
Masellis M and Lang AE: Neurogenic orthostatic hypotension and
supine hypertension in Parkinson's disease and related
synucleinopathies: Prioritisation of treatment targets. Lancet
Neurol. 15:954–966. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Shin NY, Park YW, Yoo SW, Yoo JY, Choi Y,
Jang J, Ahn KJ, Kim BS and Kim JS: Adverse effects of hypertension,
supine hypertension, and perivascular space on cognition and motor
function in PD. NPJ Parkinsons Dis. 7(69)2021.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Meade RM, Fairlie DP and Mason JM:
Alpha-synuclein structure and Parkinson's disease-lessons and
emerging principles. Mol Neurodegener. 14(29)2019.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Javanshiri K, Drakenberg T, Haglund M and
Englund E: Cardiac alpha-synuclein is Present in
alpha-synucleinopathies. J Parkinsons Dis. 12:1125–1131.
2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Isonaka R, Rosenberg AZ, Sullivan P,
Corrales A, Holmes C, Sharabi Y and Goldstein DS: Alpha-synuclein
deposition within sympathetic noradrenergic neurons is associated
with myocardial noradrenergic deficiency in neurogenic orthostatic
hypotension. Hypertension. 73:910–918. 2019.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Rodrigues LD, Oliveira LF, Shinoda L,
Scorza CA, Faber J, Ferraz HB, Britto LRG and Scorza FA:
Cardiovascular alterations in rats with Parkinsonism induced by
6-OHDA and treated with Domperidone. Sci Rep.
9(8965)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Tijero B, Gómez-Esteban JC, Lezcano E,
Fernández-González C, Somme J, Llorens V, Martínez A, Ruiz-Martínez
J, Foncea N, Escalza I, et al: Cardiac sympathetic denervation in
symptomatic and asymptomatic carriers of the E46K mutation in the α
synuclein gene. Parkinsonism Relat Disord. 19:95–100.
2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Tijero B, Gómez Esteban JC, Somme J,
Llorens V, Lezcano E, Martinez A, Rodríguez T, Berganzo K and
Zarranz JJ: Autonomic dysfunction in parkinsonian LRRK2 mutation
carriers. Parkinsonism Relat Disord. 19:906–909. 2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Park JH, Kim DH, Park YG, Kwon DY, Choi M,
Jung JH and Han K: Association of Parkinson disease with risk of
cardiovascular disease and all-cause mortality: A nationwide,
population-based cohort study. Circulation. 141:1205–1207.
2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Suri JS, Paul S, Maindarkar MA, Puvvula A,
Saxena S, Saba L, Turk M, Laird JR, Khanna NN, Viskovic K, et al:
Cardiovascular/stroke risk stratification in Parkinson's disease
patients using atherosclerosis pathway and artificial intelligence
paradigm: A systematic review. Metabolites. 12(312)2022.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Driver JA, Kurth T, Buring JE, Gaziano JM
and Logroscino G: Parkinson disease and risk of mortality: A
prospective comorbidity-matched cohort study. Neurology.
70:1423–1430. 2008.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Nam GE, Kim SM, Han K, Kim NH, Chung HS,
Kim JW, Han B, Cho SJ, Yu JH, Park YG and Choi KM: Metabolic
syndrome and risk of Parkinson disease: A nationwide cohort study.
PLoS Med. 15(e1002640)2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Qiu C, Hu G, Kivipelto M, Laatikainen T,
Antikainen R, Fratiglioni L, Jousilahti P and Tuomilehto J:
Association of blood pressure and hypertension with the risk of
Parkinson disease: The national FINRISK study. Hypertension.
57:1094–1100. 2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Liang HW, Huang YP and Pan SL: Parkinson
disease and risk of acute myocardial infarction: A
population-based, propensity score-matched, longitudinal follow-up
study. Am Heart J. 169:508–514. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Potashkin J, Huang X, Becker C, Chen H,
Foltynie T and Marras C: Understanding the links between
cardiovascular disease and Parkinson's disease. Mov Disord.
35:55–74. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Vikdahl M, Carlsson M, Linder J, Forsgren
L and Håglin L: Weight gain and increased central obesity in the
early phase of Parkinson's disease. Clin Nutr. 33:1132–1139.
2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Chohan H, Senkevich K, Patel RK, Bestwick
JP, Jacobs BM, Bandres Ciga S, Gan-Or Z and Noyce AJ: Type 2
diabetes as a determinant of Parkinson's disease risk and
progression. Mov Disord. 36:1420–1429. 2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Hassan A, Sharma Kandel R, Mishra R,
Gautam J, Alaref A and Jahan N: Diabetes mellitus and Parkinson's
disease: Shared pathophysiological links and possible therapeutic
implications. Cureus. 12(e9853)2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Athauda D and Foltynie T: Insulin
resistance and Parkinson's disease: A new target for disease
modification? Prog Neurobiol. 145-146:98–120. 2016.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lương K and Nguyễn L: Role of vitamin D in
Parkinson's disease. ISRN Neurol. 2012(134289)2012.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Kim JS, Kim YI, Song C, Yoon I, Park JW,
Choi YB, Kim HT and Lee KS: Association of vitamin D receptor gene
polymorphism and Parkinson's disease in Koreans. J Korean Med Sci.
20:495–498. 2005.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Pascale E, Purcaro C, Passarelli E,
Guglielmi R, Vestri AR, Passarelli F and Meco G: Genetic
polymorphism of angiotensin-converting enzyme is not associated
with the development of Parkinson's disease and of L-dopa-induced
adverse effects. J Neurol Sci. 276:18–21. 2009.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Castellani R, Smith MA, Richey GL and
Perry G: Glycoxidation and oxidative stress in Parkinson disease
and diffuse Lewy body disease. Brain Res. 737:195–200.
1996.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Soós J, Engelhardt JI, Siklós L, Havas L
and Majtényi K: The expression of PARP, NF-kappa B and parvalbumin
is increased in Parkinson disease. Neuroreport. 15:1715–1718.
2004.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Choi JM, Hong JH, Chae MJ, Hung NP, Kang
HS, Ma HI and Kim YJ: Analysis of mutations and the association
between polymorphisms in the cerebral dopamine neurotrophic factor
(CDNF) gene and Parkinson disease. Neurosci Lett. 493:97–101.
2011.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Fullard ME and Duda JE: A review of the
relationship between vitamin D and Parkinson disease symptoms.
Front Neurol. 11(454)2020.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Pignolo A, Mastrilli S, Davì C, Arnao V,
Aridon P, Dos Santos Mendes FA, Gagliardo C and D'Amelio M: Vitamin
D and Parkinson's disease. Nutrients. 14(1220)2022.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Barichella M, Garrì F, Caronni S, Bolliri
C, Zocchi L, Macchione MC, Ferri V, Calandrella D and Pezzoli G:
Vitamin D status and Parkinson's disease. Brain Sci.
12(790)2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Rizzoni D, Rizzoni M and Nardin M: Vitamin
D and ischaemic heart disease: A casual or A causal association?:
Commentary on: ‘Raslan E et al. Association of vitamin D
deficiency with chronic stable angina: A case-control study’. High
Blood Press Cardiovasc Prev. 26:151–155. 2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Liu X, Wang W, Tan Z, Zhu X, Liu M, Wan R
and Hong K: The relationship between vitamin D and risk of atrial
fibrillation: A dose-response analysis of observational studies.
Nutr J. 18(73)2019.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Barbarawi M, Kheiri B, Zayed Y, Barbarawi
O, Dhillon H, Swaid B, Yelangi A, Sundus S, Bachuwa G, Alkotob ML
and Manson JE: Vitamin D supplementation and cardiovascular disease
risks in more than 83 000 individuals in 21 randomized clinical
trials: A Meta-analysis. JAMA Cardiol. 4:765–776. 2019.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Luan Y and Yao Y: The clinical
significance and potential role of C-reactive protein in chronic
inflammatory and neurodegenerative diseases. Front Immunol.
9(1302)2018.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Qiu X, Xiao Y, Wu J, Gan L, Huang Y and
Wang J: C-reactive protein and risk of Parkinson's disease: A
systematic review and meta-analysis. Front Neurol.
10(384)2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Sawada H, Oeda T, Umemura A, Tomita S,
Kohsaka M, Park K, Yamamoto K and Sugiyama H: Baseline C-reactive
protein levels and life prognosis in Parkinson disease. PLoS One.
10(e0134118)2015.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Hwang O: Role of oxidative stress in
Parkinson's disease. Exp Neurobiol. 22:11–17. 2013.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Perfeito R, Cunha-Oliveira T and Rego AC:
Revisiting oxidative stress and mitochondrial dysfunction in the
pathogenesis of Parkinson disease-resemblance to the effect of
amphetamine drugs of abuse. Free Radic Biol Med. 53:1791–1806.
2012.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Ascherio A, LeWitt PA, Xu K, Eberly S,
Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB,
et al: Urate as a predictor of the rate of clinical decline in
Parkinson disease. Arch Neurol. 66:1460–1468. 2009.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Schwarzschild MA, Schwid SR, Marek K,
Watts A, Lang AE, Oakes D, Shoulson I and Ascherio A: Parkinson
Study Group PRECEPT Investigators. Hyson C, et al: Serum urate as a
predictor of clinical and radiographic progression in Parkinson
disease. Arch Neurol. 65:716–723. 2008.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Bluett B, Togasaki DM, Mihaila D, Evatt M,
Rezak M, Jain S, Schwarzschild MA, Ascherio A, Casaceli C, Curhan
GC, et al: Effect of urate-elevating inosine on early Parkinson
disease progression: The SURE-PD3 randomized clinical trial. JAMA.
326:926–939. 2021.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Borghi C and Piani F: Uric acid and risk
of cardiovascular disease: A question of start and finish.
Hypertension. 78:1219–1221. 2021.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Saito Y, Shioya A, Sano T, Sumikura H,
Murata M and Murayama S: Lewy body pathology involves the olfactory
cells in Parkinson's disease and related disorders. Mov Disord.
31:135–138. 2016.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Waragai M, Nakai M, Wei J, Fujita M,
Mizuno H, Ho G, Masliah E, Akatsu H, Yokochi F and Hashimoto M:
Plasma levels of DJ-1 as a possible marker for progression of
sporadic Parkinson's disease. Neurosci Lett. 425:18–22.
2007.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Lev N, Roncevich D, Ickowicz D, Melamed E
and Offen D: Role of DJ-1 in Parkinson's disease. J Mol Neurosci.
29:215–226. 2006.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Repici M and Giorgini F: DJ-1 in
Parkinson's disease: Clinical insights and therapeutic
perspectives. J Clin Med. 8(1377)2019.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Shimizu Y, Nicholson CK, Polavarapu R,
Pantner Y, Husain A, Naqvi N, Chin LS, Li L and Calvert JW: Role of
DJ-1 in modulating glycative stress in heart failure. J Am Heart
Assoc. 9(e014691)2020.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Tsoporis JN, Drosatos IA, Gupta S,
Amatullah H, Izhar S, Dos Santos CC, Salpeas V, Rigopoulos AG,
Toumpoulis IK, Triantafyllis AS, et al: Cytoprotective mechanisms
of DJ-1: Implications in cardiac pathophysiology. Molecules.
26(3795)2021.PubMed/NCBI View Article : Google Scholar
|
|
75
|
He R, Yan X, Guo J, Xu Q, Tang B and Sun
Q: Recent advances in biomarkers for Parkinson's disease. Front
Aging Neurosci. 10(305)2018.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Cuenca-Bermejo L, Almela P,
Navarro-Zaragoza J, Fernández Villalba E, González-Cuello AM,
Laorden ML and Herrero MT: Cardiac changes in Parkinson's disease:
Lessons from clinical and experimental evidence. Int J Mol Sci.
22(13488)2021.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Dhall R and Kreitzman DL: Advances in
levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa
and levodopa) clinical efficacy and safety. Neurology. 86 (14 Suppl
1):S13–S24. 2016.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Günaydin ZY, Özer FF, Karagöz A, Bektaş O,
Karataş MB, Vural A, Bayramoğlu A, Çelik A and Yaman M: Evaluation
of cardiovascular risk in patients with Parkinson disease under
levodopa treatment. J Geriatr Cardiol. 13:75–80. 2016.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Martignoni E, Tassorelli C, Nappi G,
Zangaglia R, Pacchetti C and Blandini F: Homocysteine and
Parkinson's disease: A dangerous liaison? J Neurol Sci. 257:31–37.
2007.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Kocer B, Guven H and Comoglu SS:
Homocysteine levels in Parkinson's disease: Is entacapone
effective? Biomed Res Int. 2016(7563705)2016.PubMed/NCBI View Article : Google Scholar
|
|
81
|
O'Suilleabhain PE, Sung V, Hernandez C,
Lacritz L, Dewey RB Jr, Bottiglieri T and Diaz-Arrastia R: Elevated
plasma homocysteine level in patients with Parkinson disease:
Motor, affective, and cognitive associations. Arch Neurol.
61:865–868. 2004.PubMed/NCBI View Article : Google Scholar
|
|
82
|
van Camp G, Flamez A, Cosyns B, Goldstein
J, Perdaens C and Schoors D: Heart valvular disease in patients
with Parkinson's disease treated with high-dose pergolide.
Neurology. 61:859–861. 2003.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Horvath J, Fross RD, Kleiner-Fisman G,
Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski
H, Pache JC, et al: Severe multivalvular heart disease: A new
complication of the ergot derivative dopamine agonists. Mov Disord.
19:656–662. 2004.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Tran T, Brophy JM, Suissa S and Renoux C:
Risks of cardiac valve regurgitation and heart failure associated
with ergot- and non-ergot-derived dopamine agonist use in patients
with Parkinson's disease: A systematic review of observational
studies. CNS Drugs. 29:985–998. 2015.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Kho J, Ioannou A, Mandal AKJ, Cox A, Nasim
A, Metaxa S and Missouris CG: Long term use of donepezil and QTc
prolongation. Clin Toxicol (Phila). 59:208–214. 2021.PubMed/NCBI View Article : Google Scholar
|
|
86
|
de Baat EC, Mulder RL, Armenian S, Feijen
EA, Grotenhuis H, Hudson MM, Mavinkurve-Groothuis AM, Kremer LC and
van Dalen EC: Dexrazoxane for preventing or reducing cardiotoxicity
in adults and children with cancer receiving anthracyclines.
Cochrane Database Syst Rev. 9(CD014638)2022.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Mei M, Zhou Y, Liu M, Zhao F, Wang C, Ding
J, Lu M and Hu G: Antioxidant and anti-inflammatory effects of
dexrazoxane on dopaminergic neuron degeneration in rodent models of
Parkinson's disease. Neuropharmacology. 160(107758)2019.PubMed/NCBI View Article : Google Scholar
|
